Compound Profile Scientific & Efficacy Data C 194 H 312 N 54 O 59 S 2 Molecular Formula 4409 g/mol Molecular Weight 159-195 hours (~7-8 days) Half-Life ~100% (subcutaneous) Bioavailability 1415456-99-3 CAS # 171397054 PubChem ID Developed By 2021 Thomas Kruse Novo Nordisk Primary Benefits Exceptional appetite suppression through dual amylin and calcitonin receptor activation, creating powerful and sustained satiety signals Impressive 10-15% weight loss alone, or 20%+ when combined with semaglutide in the CagriSema combination Uniquely designed to complement GLP-1 medications through an independent mechanism, dramatically enhancing results when combined Amino Acid Sequence Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (acylated with C18 diacid via gamma-Glu linker) Dosing How much do I take
Human trials and animal models are reported separately
Kua-zarnu trakta aizsardzba BPC 157 skotnji tika izolts no kua sulas, un tam ir aizsargjoa iedarbba uz kua-zarnu traktu
Excessive combined peptide exposure can overwhelm cellular systems, reducing overall efficacy
According to a 2012 study on a serum containing barley bioengineered epidermal growth factor, "clinical evaluations showed statistically significant improvement in the appearance of fine lines and rhytids, skin texture, pore size , and various dyschromatic conditions apparent within the first month of use, and continuing improvement trends for the duration of the study" (which was 3 months)